You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ANYTIME, ANYPLACE LEARNING FOR CRITICAL CARE

    SBC: ACADEMIC EDGE, INC.            Topic: N/A

    completion, the entire course will provide a professional certificate with continuing nursing education contact hours or can be transferred as academic credit in an undergraduate-nursing program. The model for the OCPP to be developed in this project has three components: didactic core content, clinical practicum, and a Virtual Center of Best Practices. The core ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. ANTI-ANDROGENIC MECHANISM OF A NEW COMPOUND

    SBC: ANDROSCIENCE CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patie ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. NASALLY-DELIVERED MUCOSAL SUBUNIT VACCINE FOR PLAGUE

    SBC: BIODEFENSE TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed a plant-based adjuvant/carrier:antigen fusion technology that offers significant advantages over conventional injectable vaccination regimes including: safety, mucosal efficacy, ease of delivery, rapid scalability, unlimited supply potential, and cost-savings. This technology has significant potential in contributing to biodefense strategies ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT

    SBC: BIOMOD SURFACES            Topic: N/A

    Medium (6-8mm) and small (

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT

    SBC: BIOMOD SURFACES            Topic: N/A

    Medium (6-8mm) and small (

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  9. NANOFIBER TECHNOLOGY IN SMALL-DIAMETER VASCULAR GRAFTS

    SBC: BIOMOD SURFACES            Topic: N/A

    There is no small-diameter vascular prosthesis that is capable of emulating the biologic and physical properties of the normal arterial wall. The goal of this proposal is to develop a small-diameter prosthetic vascular graft using nanofiber technology. Our hypothesis is creating a nanofibrous vascular graft by electrospinning an ionic polyurethane will result in a graft that possesses properties s ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  10. DEVELOPMENT OF A MIDDLE EAR BALLOON IMPLANT

    SBC: BOSTON MEDICAL PRODUCTS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of a new type of middle ear implant, a "middle ear balloon" is proposed. This implant is intended to restore hearing in non-aerated ears by creating and permanently maintaining an air or gas-filled space within the middle ear. Non-aerated middle ears resulting from eustachian tube dysfunction camonly occur in chronic otitis media (COM) and in otitis ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government